Initiate a Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Feb 2025
- Due
- 30 Sep 2025
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia Psychosis in the third quarter of 2025”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 study of ACP-204 (remlifanserin) for Lewy Body Dementia Psychosis in September 2025, meeting the third-quarter deadline.
-
A Acadia Pharmaceuticals Inc. 8-K filed 2025-11-05
“Continued to advance the Company's pipeline with the initiation of a Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis” ✓ confirmed on the page
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2025-11-06
“We initiated an additional Phase 2 study of ACP-204 in LBDP in September 2025.” ✓ confirmed on the page
Market reaction: the shares moved +3.9% against the S&P 500 over the three sessions around the disclosure (4 Nov 2025 to 7 Nov 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 study of ACP-204
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ACAD-002595 · Corrections policy